Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Nivolumab may be beneficial for recurrent or metastatic cervical cancer

Key clinical point: Nivolumab may have some potential for treating recurrent and metastatic gynecologic cancers.

Major finding: 26.3% of patients with cervical cancer and 20% with vaginal/vulvar cancers experienced an objective response.

Study details: A cohort within the phase 1/2 CheckMate 358 trial for patients with virus-associated tumors.

Disclosures: Bristol-Myers Squibb funded the study. Several of Dr. Naumann’s associates reported relationships with the company and four others are employed by Bristol-Myers Squibb.


Naumann RW et al. J Clin Onc. 2019 Sep 5. doi: 10.1200JCP.19.00739